病毒性肝炎防治新形势下对中医药防治肝纤维化的思考

池晓玲; 萧焕明

doi:10.3969/j.issn.1001-5256.2018.04.003

病毒性肝炎防治新形势下对中医药防治肝纤维化的思考

DOI: 10.3969/j.issn.1001-5256.2018.04.003

广东省中医院肝病科

详细信息

中图分类号: R575.2
计量
- 文章访问数: 2634
- HTML全文浏览量: 68
- PDF下载量: 477
- 被引次数: 0
出版历程
- 出版日期: 2018-04-20

Traditional Chinese medicine prevention and treatment of liver fibrosis under the new situation of prevention and treatment of viral hepatitis

The Liver Department of Guangdong Provincial Hospital of Traditional Chinese Medicine

摘要

摘要:
抗肝纤维化是中医药防治病毒性肝炎特色优势的重要体现。《2016-2021年全球卫生部门病毒性肝炎战略》、《中国病毒性肝炎防治规划（2017-2020）》的发布为中医药防治肝纤维化带来机遇。如何提高肝纤维化的疗效、研发更多抗肝纤维化的有效中药新药是新形势下中医药防治肝纤维化研究的挑战。以提高临床疗效为目的,从肝纤维化发生发展的不同阶段着手,发挥中医辨证论治的优势,早期干预,并联合精准医学、中医特色慢病管理等手段开展临床与基础研究,进一步建立并推广应用中医药防治肝纤维化的临床诊疗指南及中医药防治肝纤维化的中医特色慢病管理指南是未来中医药防治肝纤维化研究的重要内容。
- 肝硬化 /
- 肝炎,病毒性,人 /
- 中医疗法
Abstract:
The prevention and treatment of liver fibrosis is an important embodiment of the characteristic advantage of traditional Chinese medicine (TCM) in the prevention and treatment of viral hepatitis.The release of Global Health Sector Strategy on Viral Hepatitis, 2016-2021 and Viral Hepatitis Prevention and Control Plan of China (2017-2020) brings opportunities to TCM prevention and treatment of liver fibrosis.There are still challenges in the research on TCM prevention and treatment of liver fibrosis, including how to improve the outcome of liver fibrosis and the research and development of more effective TCM new drugs for liver fibrosis.With the purpose of improving the clinical effect, we will start from the different stages of the development and progression of liver fibrosis, use the advantages of TCM syndrome differentiation-based treatment, provide early intervention, conduct clinical and basic research with the combination of precision medicine and TCM management of chronic diseases, and further establish and promote the application of the guidelines for clinical diagnosis and treatment of liver fibrosis and the TCM management guidelines for chronic diseases, which are the important contents of TCM prevention and treatment of liver fibrosis in future.
- liver cirrhosis /
- hepatitis, viral, human /
- TCM therapy

HTML全文

参考文献(15)

[1] World Health Organization.Global health sector strategy on viral hepatitis 2016-2021[EB/OL]. (2016-06) [2018-03].http://www.who.int/hepatitis/strategy2016-2021/ghss-hep/zh/.世界卫生组织.《2016-2021年全球卫生部门病毒性肝炎战略》[EB/OL]. (2016-06) [2018-03].http://www.who.int/hepatitis/strategy2016-2021/ghss-hep/zh/

[2]CHANG TT, LIAW YF, WU SS, et al.Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B[J].Hepatology, 2010, 52 (3) :886-893.

[3]LOK AS.Hepatitis:long-term therapy of chronic hepatitis B reverses cirrhosis[J].Nat Rev Gastroenterol Hepatol, 2013, 10 (4) :199-200.

[4]MARCELLIN P, GANE E, BUTI M, et al.Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B:a 5-year open label follow up study[J].Lancet, 2013, 381 (9865) :468-475.

[5]WANG BQ, SUN YM, YOU H, et al.Pathological assessment of liver fibrosis regression[J].J Clin Hepatol, 2017, 33 (3) :435-437. (in Chinese) 王冰琼, 孙亚朦, 尤红, 等.肝纤维化逆转的病理评估[J].临床肝胆病杂志, 2017, 33 (3) :435-437.

[6]ZHOU JL, WEI W, YOU H.Progress in clinical studies of noninvasive early diagnosis of liver fibrosis and cirrhosis[J].J Clin Hepatol, 2014, 30 (7) :604-607. (in Chinese) 周家玲, 魏巍, 尤红.肝纤维化无创诊断技术的临床研究及进展[J].临床肝胆病杂志, 2014, 30 (7) :604-607.

[7]ZHANG X, XU Y, CHEN JM, et al.Huang Qi Decoction prevents BDL-induced liver fibrosis through inhibition of notch signaling activation[J].Am J Chin Med, 2017, 45 (1) :85-104.

[8]LIU S, WANG XM, YANG GW.Effect of RUANGANJIEDU decoction inhibit experimental hepatic fibrosis of rats[J].Afr J Tradit Complement Altern Med, 2017, 14 (1) :242-250.

[9]BAI GP, YAN GH, WANG GJ, et al.Anti-hepatic fibrosis effects of a novel turtle shell decoction by inhibiting hepatic stellate cell proliferation and blocking TGF-beta 1/Smad signaling pathway in rats[J].Oncol Rep, 2016, 36 (5) :2902-2910.

[10]LU W, GAO YH, WANG ZZ, et al.Effects of Anluohuaxianwan on transforming growth factor-beta1 and related signaling pathways in rats with carbon tetrachloride-induced liver fibrosis[J].Chin J Hepatol, 2017, 25 (4) :257-262. (in Chinese) 卢玮, 高玉华, 王珍子, 等.安络化纤丸对肝纤维化大鼠转化生长因子β1及相应信号通路的影响[J].中华肝脏病杂志, 2017, 25 (4) :257-262.

[11]XI SY, SHI MM, JIANG XQ, et al.The effects of Tao-Hong-Si-Wu on hepatic necroinflammatory activity and fibrosis in a murine model of chronic liver disease[J].J Ethnopharmacol, 2016, 180:28-36.

[12]ZHANG CZ, XIAO HM, SHI MJ, et al.Model of traditional Chinese medicine of chronic hepatitis B in the management of chronic disease[J].Chin J Integr Tradit West Med Liver Dis, 2016, 26 (3) :181-182, 184. (in Chinese) 张朝臻, 萧焕明, 施梅姐, 等.慢性乙型肝炎慢病管理中医模式初探[J].中西医结合肝病杂志, 2016, 26 (3) :181-182, 184.

[13]LIU LX.Evaluation of the TCM chronic disease management in community patients with chronic hepatitis B[D].Guangzhou:Guangzhou Univ Chin Med, 2017. (in Chinese) 刘乐鑫.中医特色慢病管理模式在社区慢性乙型病毒性肝炎中的效果评价[D].广州:广州中医药大学, 2017.

[14]WANG G, LI ZH, LI H, et al.Metabolic profile changes of CCl4-liver fibrosis and inhibitory effects of Jiaqi Ganxian granule[J].Molecules, 2016, 21 (6) :698.

[15]ZHANG HY, WANG XN, HU P, et al.Serum metabolomic characterization of liver fibrosis in rats and anti-fibrotic effects of YinChen-Hao-Tang[J].Molecules, 2016, 21 (1) :126.

施引文献

资源附件(0)

访问统计